School of Life Sciences, Kingston University, London KT1 2EE, United Kingdom.
J Clin Endocrinol Metab. 2014 Mar;99(3):808-16. doi: 10.1210/jc.2013-2872. Epub 2014 Jan 13.
A comprehensive liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay was developed to quantify 10 forms of vitamin D in sera from healthy adults and patients suffering from rheumatoid arthritis (RA), type 1 diabetes (T1-D), and Alzheimer disease (AD).
The rapid assay, validated according to US Food and Drug Administration guidelines with Chromsystems and DEQAS samples, was applied to 36 nonhealthy sera samples (41.7% male, age range of 14-95, mean = 54.00 ± 21.98 years), consisting of individuals with RA, T1-D, and AD (n = 12 each) and was compared to samples from 32 healthy individuals (50% male, age range of 19-90, mean = 58.83 ± 22.93 years).
The key findings are (1) the 23R,25-dihydroxyvitamin D3 form was quantified for the first time (healthy = 0.427 ± 0.633 nmol/L; combined disease = 0.395 ± 0.483 nmol/L), (2) the 3-epi-25-hydroxyvitamin D3 metabolite was found in all groups with significantly higher concentration in the diseased samples [healthy = 6.093 ± 6.711 nmol/L; combined disease = 22.433 ± 13.535 nmol/L, t(52.5) = -6.411; P < .001], (3) a significant difference was found for the active form (1α-25-dihydroxyvitamin D3) between health (0.027 ± 0.035 nmol/L) and disease (0.433 ± 0.870 nmol/L) [t(35.1) = -2.797, P = 0.008], and (4) there was no significant correlation between the total circulating and total active forms in either the disease or healthy group (r = -0.180 and -0.274, respectively, with no difference between the correlation coefficients, z = -0.389, P = .697). Receiver operating characteristic curve analysis showed good sensitivity and specificity for using the 3-epi-25-hydroxyvitamin D concentration to predict disease status (area under the curve = 0.880, P < .001). Discriminant function analysis using concentrations of 23R,25-dihydroxyvitamin D3, 25-hydroxyvitamin D2, and 3-epi-25-hydroxyvitamin D classified 94.4% (91.7% in cross-validation) of the cases correctly.
This study reveals significant differences between health and disease with epimers having the potential to relate to disease. The potential implications of the information gleaned from measuring all forms warrant application of more comprehensive assays for future clinical studies investigating the link between vitamin D and health.
建立了一种用于定量检测健康成年人和类风湿关节炎(RA)、1 型糖尿病(T1-D)和阿尔茨海默病(AD)患者血清中 10 种维生素 D 形式的液相色谱-串联质谱(LC-MS/MS)分析方法。
根据美国食品和药物管理局的指南,使用 Chromsystems 和 DEQAS 样本对快速检测方法进行了验证,该方法应用于 36 份非健康血清样本(41.7%为男性,年龄范围为 14-95 岁,平均=54.00±21.98 岁),包括 RA、T1-D 和 AD 患者(各 12 例),并与 32 名健康个体(50%为男性,年龄范围为 19-90 岁,平均=58.83±22.93 岁)的样本进行比较。
主要发现包括:(1)首次定量检测了 23R,25-二羟维生素 D3 形式(健康个体=0.427±0.633 nmol/L;合并疾病个体=0.395±0.483 nmol/L);(2)发现了 3-表-25-羟维生素 D3 代谢物,所有组均存在该代谢物,且疾病样本中的浓度显著更高[健康个体=6.093±6.711 nmol/L;合并疾病个体=22.433±13.535 nmol/L,t(52.5)=-6.411;P<0.001];(3)活性形式(1α-25-二羟维生素 D3)在健康个体(0.027±0.035 nmol/L)和疾病个体(0.433±0.870 nmol/L)之间存在显著差异[t(35.1)=-2.797,P=0.008];(4)无论是在疾病组还是健康组,总循环和总活性形式之间均无显著相关性(r=-0.180 和-0.274,相关系数之间无差异,z=-0.389,P=0.697)。受试者工作特征曲线分析显示,使用 3-表-25-羟维生素 D 浓度预测疾病状态具有良好的敏感性和特异性(曲线下面积=0.880,P<0.001)。使用 23R,25-二羟维生素 D3、25-羟维生素 D2 和 3-表-25-羟维生素 D 的浓度进行判别函数分析,正确分类了 94.4%(交叉验证中为 91.7%)的病例。
本研究揭示了健康和疾病之间的显著差异,并且外消旋体有可能与疾病相关。从测量所有形式中获取信息的潜在意义需要应用更全面的检测方法,以进行未来研究维生素 D 与健康之间关系的临床研究。